Novo Nordisk’s Oral Wegovy Pill Surges Past Eli Lilly, but Generics and Price Pressure Loom
Novo Nordisk’s oral Wegovy pill leads Eli Lilly’s Foundayo 2-to-1 in US prescriptions, but faces generic competition in…
Novo Nordisk’s Oral Wegovy Pill Leaves Eli Lilly in the Dust as Pipeline Battles Loom
Novo Nordisk shares jump 6.4% as oral Wegovy prescriptions dwarf Eli Lilly’s rival, while pivotal CagriSema trial data…
Novo Nordisk’s AI Drive Meets a Harsh Pricing Reality
Novo Nordisk shares fall 50% from highs on 2026 profit warning, US market loss to Eli Lilly, and…
Novo Nordisk’s Buyback Buffer Against a Perfect Storm
Novo Nordisk launches a massive share buyback as it faces its first revenue decline in 25 years, intense…
Novo Nordisk Faces Mounting Pressure as Rival Gains Ground
Novo Nordisk faces intense competition from Eli Lilly in the $100B obesity drug market, with clinical data and…